BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37133437)

  • 21. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.
    Wei R; Zhu WW; Yu GY; Wang X; Gao C; Zhou X; Lin ZF; Shao WQ; Wang SH; Lu M; Qin LX
    Int J Cancer; 2021 Mar; 148(5):1233-1244. PubMed ID: 33205453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
    Liu Y; Shen B; Huang T; Wang J; Jiang J
    PLoS One; 2023; 18(7):e0288013. PubMed ID: 37406019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
    Chen S; Zhao E
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study.
    Zhang C; Yao R; Chen J; Zou Q; Zeng L
    Medicine (Baltimore); 2021 Jan; 100(3):e24135. PubMed ID: 33546025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis.
    Mou L; Pu Z; Luo Y; Quan R; So Y; Jiang H
    Front Immunol; 2023; 14():1036562. PubMed ID: 36936948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
    Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
    BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making.
    Shi Y; Wang Y; Yang R; Zhang W; Zhang Y; Feng K; Lv Q; Niu K; Chen J; Li L; Zhang Y
    Front Endocrinol (Lausanne); 2022; 13():1090324. PubMed ID: 36605944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Pyroptosis Gene Signature Related Molecular Pattern, Clinical Implication, and Tumor Immunity in Hepatocellular Carcinoma`.
    Li YT; Zeng XZ
    Comb Chem High Throughput Screen; 2023; 26(7):1324-1336. PubMed ID: 36017840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
    Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
    Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
    J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
    Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
    Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
    Xiong C; Wang G; Bai D
    Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a 4-lncRNA combined prediction model for patients with hepatocellular carcinoma.
    Xu C; Qi X
    Adv Clin Exp Med; 2022 Oct; 31(10):1087-1097. PubMed ID: 35913371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
    He D; Liao S; Cai L; Huang W; Xie X; You M
    BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Analysis of Prognostic Value and Immune Infiltration of Src Family Kinases in Hepatocellular Carcinoma.
    Yao D; Deng Y; Zhang S; Liang L; Zhang L; Weng S; Chen S
    Front Biosci (Landmark Ed); 2023 May; 28(5):90. PubMed ID: 37258470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
    Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
    BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
    Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
    Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.